Phase 3 Clinical Trials With Primary Completion Dates in August 2021

This is a list of Phase 3 trials with primary completion dates in August 2021 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
APLIF Appili Therapeutics Inc. 2021-08-01 Phase 3 NCT04600895 The Prevent Severe COVID-19 (PRESECO) Study
AUPH Aurinia Pharmaceuticals Inc. 2021-08-01 Phase 3 NCT03597464 Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin
CDTX Cidara Therapeutics, Inc. 2021-08-01 Phase 3 NCT03667690 Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
CFRX ContraFect Corporation 2021-08-01 Phase 3 NCT04160468 Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase
CTSO Cytosorbents Corporation 2021-08-01 Phase 3 NCT04643639 Assessing the Effects of CytoSorb Hemoperfusion on the Development on Immunoparalysis
CVAC CureVac N.V. 2021-08-01 Phase 3 NCT04838847 A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19
ERYP ERYTECH Pharma S.A. 2021-08-01 Phase 3 NCT03665441 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC
IPSEY Ipsen S.A. 2021-08-01 Phase 3 NCT01957436 A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer
KRYS Krystal Biotech, Inc. 2021-08-01 Phase 3 NCT04491604 The Objective of This Study is to Compare the Efficacy and Safety of Beremagene Geperpavec (B-VEC) Topical Gel With That of Placebo for the Treatment of Dystrophic Epidermolysis Bullosa (DEB).
NMTR 9 Meters Biopharma, Inc. 2021-08-01 Phase 3 NCT03569007 Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms
RIGL Rigel Pharmaceuticals, Inc. 2021-08-01 Phase 3 NCT04629703 Double-Blind, Randomized, Placebo-Controlled, Adaptive Design, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects
TBPH Theravance Biopharma, Inc. 2021-08-01 Phase 3 NCT03750552 Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
UTHR United Therapeutics Corporation 2021-08-01 Phase 3 NCT01560637 An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension